Mild-to-Moderate Depression: The Evidence-Based Supplement Protocol

← Back to articles

For moderate-to-severe major depressive disorder, SSRIs and psychotherapy remain first-line. For mild-to-moderate depression and as augmentation in partial responders, several supplements have credible RCT evidence — some with head-to-head trials against SSRIs. The five with the strongest data: saffron, SAMe, EPA-dominant omega-3, vitamin D in deficiency, and St. John's Wort (with critical drug-interaction caveats).

Saffron, 30 mg Daily

A 2019 meta-analysis of 11 RCTs concluded that saffron 30 mg daily produced antidepressant effects comparable to fluoxetine and imipramine in mild-to-moderate depression, with substantially fewer side effects. The strongest trials are Iranian; replication in Western cohorts is ongoing. See our saffron review.

SAMe (S-Adenosyl-L-Methionine), 800–1,600 mg Daily

SAMe is a methyl donor required for neurotransmitter synthesis. A 2002 AHRQ meta-analysis concluded it outperformed placebo and was comparable to tricyclic antidepressants for depressive symptoms. Used in Europe as a prescription drug. Side effects: GI upset, occasional anxiety/agitation in bipolar-spectrum patients (screen for mania risk). See our SAMe piece.

EPA-Dominant Omega-3, 1–2 g EPA Daily

A 2019 meta-analysis of 26 RCTs concluded that EPA-dominant omega-3 (≥60% EPA) produced clinically meaningful antidepressant effects, particularly as augmentation to SSRIs. Pure DHA does not appear to work. See our omega-3 depression piece.

Vitamin D — Repletion in Deficiency Only

Vitamin D deficiency is associated with depression in observational data. RCTs in already-replete adults are null. Repletion in deficient adults (≤20 ng/mL) modestly reduces depressive symptoms. Test and treat — don't dose blindly. See vitamin D dose guide.

St. John's Wort, 600–1,800 mg Standardized Extract Daily

A 2017 Cochrane review of 35 RCTs in 6,993 adults concluded St. John's Wort outperformed placebo and was comparable to standard antidepressants for mild-to-moderate depression. Critical caveat: it is a strong CYP3A4 inducer that reduces levels of oral contraceptives, warfarin, cyclosporine, antiretrovirals, and triptans, and combined with SSRIs can produce serotonin syndrome. See our drug-interaction piece.

What NOT to Take

Avoid 5-HTP if you are on any SSRI/SNRI/MAOI — serotonin syndrome risk. See our 5-HTP piece. Avoid kava — hepatotoxicity. Skip "mood support" megavitamin formulas — the studied ingredients are at subclinical doses. Don't replace evidence-based therapy in moderate-to-severe MDD with supplements alone. Avoid stacking St. John's Wort with any other serotonergic agent without prescriber input.

How to Run the Protocol

For mild depression: saffron 30 mg + EPA 1 g daily for 8 weeks. Re-evaluate with PHQ-9. For mild-to-moderate: SAMe 800–1,600 mg daily or St. John's Wort 600–900 mg standardized extract (NEVER concurrent with SSRIs). Add vitamin D if 25-OH-D <30 ng/mL. CBT and aerobic exercise have larger effects than any supplement. For moderate-to-severe depression, see a psychiatrist; supplements are augmentation, not replacement.